Article Text

Download PDFPDF
CASE REPORT
Retained products of conception in hysteroscopy in a patient with breast cancer on tamoxifen
  1. Dhilshad Qadir,
  2. Monica Chua and
  3. Suzanna Sulaiman
  1. Department of Obstetrics and Gynaecology, KK Women’s and Children’s Hospital, Singapore
  1. Correspondence to Dr Dhilshad Qadir, dhilshad.qadir{at}mohh.com.sg

Abstract

Tamoxifen is a selective oestrogen receptor modulator widely used in breast cancer treatment, with good survival rates. Its partial agonist action on other tissues such as the uterus, however, promotes the development of endometrial hyperplasia and cancer. It appears that tamoxifen does not alter the age of menopause and women may still get pregnant while on tamoxifen. We present the case of a 47-year-old Chinese woman with breast cancer on tamoxifen, who presented with one episode of heavy per vaginal bleeding after 2 years of amenorrhoea. Her urine pregnancy test was negative and the ultrasound scan was suspicious for malignancy. She underwent a hysteroscopic evaluation for abnormal bleeding on tamoxifen. Histopathology confirmed products of conception. This case illustrates the importance of understanding the rise and decline of human chorionic gonadotropin in pregnancy, as well as the pivotal role of contraception despite having amenorrhoea on tamoxifen.

  • obstetrics, gynaecology and fertility
  • cancer - see oncology
  • pregnancy
  • breast cancer
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors DQ: took the lead and was the main author of the manuscript. MC: involved in editing the manuscript. SS: in-charge of the patient; involved in the conception and editing of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Obtained.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.